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Cumulative scores based on plasma 
D-dimer and serum albumin levels predict 
survival in esophageal squamous cell 
carcinoma patients treated with transthoracic 
esophagectomy
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Abstract 
Background: Recently, studies have shown that plasma D‑dimer and serum albumin are prognostic markers for 
esophageal cancer. The purpose of this study was to evaluate a novel prognostic scoring system—DA score (combi‑
nation of preoperative plasma D‑dimer and serum albumin levels)—and analyze the association between survival of 
patients with esophageal squamous cell carcinoma (ESCC) and their Glasgow prognostic score.
Methods: In this retrospective study, preoperative biochemical markers and clinicopathologic factors in 260 ESCC 
patients treated with transthoracic esophagectomy were reviewed. According to receiver operating characteristic 
analysis, the cutoff values of D‑dimer and albumin were defined as 0.5 μg/mL and 43.8 g/L, respectively. Patients with 
high D‑dimer levels (≥0.5 μg/mL) and low albumin levels (<43.8 g/L) were assigned a score of 2, those with only one 
of the two abnormalities were assigned a score of 1, and those with neither of the two abnormalities were assigned a 
score of 0.
Results: ESCC patients with a DA score of 0, 1, and 2 numbered 55, 116, and 89, respectively. Survival analysis showed 
that patients with a DA score of 2 had lower overall survival (OS) rates than those with DA scores of 1 and 0 (37.1% vs. 
52.6% and 76.4%, P < 0.001); similar findings were observed for disease‑free survival (DFS) rates (32.6% vs. 44.8% and 
67.3%, P < 0.001). In addition, the predictive value of the DA score was also significant in patients with stages I–IIA and 
stages IIB–IV ESCC. Multivariate Cox regression analyses indicated that hazard ratios (HRs) for predicting OS of patients 
with DA scores 1 and 2 were 2.25 (P = 0.010) and 3.14 (P < 0.001), respectively, compared with those with a DA score 
of 0, and HRs for predicting DFS of patients with DA scores of 1 and 2 were 1.86 (P = 0.023) and 2.68 (P < 0.001), 
respectively, compared with those with a DA scores of 0.
Conclusions: Our study suggests that preoperative DA scores are notably associated with postoperative survival of 
ESCC patients.
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Background
Esophageal cancer (EC) is the eighth most common can-
cer worldwide and the sixth leading cause of death due 
to cancer [1]. In China, the predominant histological type 
of EC is esophageal squamous cell carcinoma (ESCC), 
which accounts for 90% of ECs [2–4]. Despite multidis-
ciplinary treatments that have been developed for ESCC, 
including surgical resection and neoadjuvant chemora-
diation therapy, transthoracic esophagectomy remains 
the primary therapeutic strategy for locoregional ESCC 
[5–7]. Unfortunately, even after surgical resection, ESCC 
patients still have a high postoperative recurrence rate 
and poor prognosis, with only a 5-year survival rate rang-
ing 26.2%–49.4% [8]. Therefore, identifying a simple and 
instructive indicator that could identify ESCC patients 
with high risk of tumor recurrence and poor prognosis is 
urgently needed.
To date, clinical stages, pathologic findings, and per-
formance statuses have been considered the predomi-
nant prognostic factors in patients with common solid 
tumors. However, clinical staging is often inaccurate 
despite the use of high-resolution computed tomogra-
phy (CT), and definition of performance status is some-
times subjective [9, 10]. Recently, the Glasgow prognostic 
score (GPS), which is based on C-reactive protein (CRP) 
and albumin levels as well as reflects inflammation and 
nutritional status, was used as a prognostic indictor for 
numerous cancers [11]. However, some studies indicated 
that systemic inflammation and malnutrition are not sig-
nificant in operable ESCC patients, leading to decreased 
clinical application of GPS [12]. Therefore, it is impera-
tive to identify a novel prognostic scoring system that can 
improve the clinical outcome of ESCC patients.
In previous studies, coagulation abnormalities were 
commonly seen in patients with malignant tumors 
[13–15]. Systemic activation of blood coagulation and 
procoagulant changes were associated with angiogen-
esis, tumor cell invasion and progression, and metastatic 
spreading [16]. D-dimer, which is an end-degradation 
product of fibrin, indicates the activation of hemostasis 
and the hypercoagulable state. Elevated D-dimer levels 
were observed in acute venous thromboembolism, preg-
nancy, infectious diseases, surgery, as well as cancers [17]. 
Moreover, recent studies showed that elevated D-dimer 
levels predicted poor prognosis in various types of cancer, 
including breast cancer, lung cancer, ovarian cancer, and 
EC [16, 18]. Therefore, we hypothesized that the combina-
tion of D-dimer and albumin, which reflects malnutrition 
and poor survival in cancer patients [19–21], may provide 
a simple and objective prognostic scoring system for ESCC 
patients. In this study, we devised a novel prognostic scor-
ing system, called the DA score (combination of D-dimer 
and albumin levels), and analyzed the clinical significance 
of the DA score for predicting the prognosis of ESCC 
patients who underwent transthoracic esophagectomy.
Methods
Patient selection
In this study, the data of 260 ESCC patients who under-
went transthoracic esophagectomy between Decem-
ber 2004 and December 2010 in Sun Yat-sen University 
Cancer Center, Guangzhou, China were analyzed retro-
spectively. The criteria for case selection were as follows: 
(1) pathologic diagnosis of primary squamous cell carci-
noma; (2) no history of preoperative adjuvant therapy; 
and (3) preoperative plasma D-dimer levels, serum albu-
min levels, and serum CRP levels obtained within 1 week 
before surgery. The following data were also recorded for 
all patients: age, sex, tumor diameter, tumor location, 
TNM stage, T category, N category, pathologic grade, 
history of hepatitis B virus infections, and family history 
of cancer. TNM classification was evaluated using the 6th 
edition of the Union for International Cancer Control 
staging. This study was approved by the medical ethics 
committee of Sun Yat-sen University Cancer Center, and 
informed consent was obtained from all patients.
D‑dimer, albumin, and CRP measurement
As a part of clinical routine examinations, pretreat-
ment plasma D-dimer levels, serum albumin levels, and 
CRP levels were measured 24  h to 1  week before sur-
gery. Plasma D-dimer values were analyzed by a latex-
enhanced immunoturbidimetric assay and a Sysmex CA 
7000 system (Sysmex Corporation, Japan) according to 
the manufacturer’s instructions. Serum albumin levels 
and CRP levels were measured by using a Hitachi 7600-
020 automatic biochemical analyzer (Hitachi, Japan). 
The optimal cutoff values of D-dimer and albumin in our 
study were verified using Youden’s index (YI) from the 
receiver operating characteristic (ROC) curve for ESCC 
prediction. The survival status was inserted into the YI to 
define the cutoff value as described by Huang et al. [22] 
and Liu et  al. [23]. A high level of preoperative plasma 
D-dimer was defined as ≥0.5 μg/mL, and a low level of 
preoperative serum albumin was defined as <43.8 g/L.
D‑dimer and albumin (DA) score
ESCC patients with high D-dimer levels (≥0.5 μg/mL) and 
low albumin levels (<43.8 g/L) were assigned a score of 2, 
those with only one of the two biochemical abnormalities 
were assigned a score of 1, and those with neither of the 
two biochemical abnormalities were assigned a score of 0.
GPS
GPS was defined as described previously [11]. Specifi-
cally, patients with low CRP (<10 mg/L) and high albumin 
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levels (≥35  g/L) were assigned a score of 0, those with 
one of the two biochemical abnormalities were assigned 
a score of 1, and those with both high CRP levels and low 
albumin levels were assigned a score of 2.
Follow‑up
Postoperative follow-up was performed by using gas-
troscopy and CT scanning every 3–6  months for the 
first 3 years, then annually until death or the end of the 
present study. In total, 260 ESCC patients were followed 
up for 2–91  months, with a median follow-up time of 
40.5  months and a median survival time of 35  months 
(1–91  months). The last scheduled follow-up was on 
April 20, 2015. Overall survival (OS) was defined as the 
interval from the date of surgery to the date of death 
from any causes. Disease-free survival (DFS) was defined 
as the interval from the time of surgery to the date of 
local relapse or distant metastasis.
Statistical analysis
Statistical analysis was performed using the SPSS 16.0 
software package (SPSS, Chicago, IL, USA). The Chi 
square test was used to assess the association between 
the DA scores and clinicopathologic variables of ESCC 
patients. OS and DFS curves were plotted by using the 
Kaplan–Meier method and evaluated by using the log-
rank test. Univariate and multivariate survival analyses 
were performed by using the Cox regression model. Dif-
ferences were considered statistically significant when 
the P value was <0.05.
Results
Patient characteristics
The characteristics of the 260 ESCC patients are 
shown in Table  1. The median age was 59  years (range, 
39–83 years), and 83.5% of patients were males. Tumors 
were observed in the upper-thoracic esophagus in 8.1% 
of patients, in the mid-thoracic esophagus in 63.5% of 
patients, and in the lower-thoracic esophagus in 28.5% 
of patients. The median diameter of the tumor was 4 cm 
(range 1–10 cm). The histopathologic grades were well/
moderate in 68.8% of patients and poor in 31.2% of 
patients. Of the 260 patients, tumor invasion depths of 
T1/T2 and T3/T4 were observed in 50 (19.2%) and 210 
(80.8%) patients, respectively; 153 (58.8%) had positive 
lymph node metastases; and only 3 (1.2%) had distant 
metastases (M1) before surgery, and metastasis sites 
were completely excised. Before treatment, 158 (60.8%) 
patients were diagnosed with stage IIB disease or higher. 
Hepatitis B surface antigen (HBsAg) was positive in 19 
(7.4%) of 257 patients; three patients were absent of the 
status of HBsAg. Of the 260 patients, 24 (9.2%) reported 
a first-degree family history of EC.
Association between preoperative DA scores 
and clinicopathologic characteristics of ESCC
In the total study population, the median preoperative 
plasma D-dimer level was 0.5 (25th–75th percentile: 
0.3–0.7) μg/mL, and the median preoperative serum 
albumin level was 43.1 (25th–75th percentile: 40.7–45.0) 
g/L. Of the 260 patients, 138 (53.1%) showed elevated 
preoperative D-dimer levels (≥0.5  μg/mL), and 156 
(60.0%) showed decreased preoperative albumin lev-
els (<43.8 g/L). Also of the 260 patients, 55 (21.2%) had 
a preoperative DA score of 0, 116 (44.6%) had a preop-
erative DA score of 1, and 89 (34.2%) had a preoperative 
DA score of 2 (Table 1). The association between preop-
erative DA scores and postoperative clinicopathologic 
characteristics is shown in Table  1. Older patients had 
higher preoperative DA scores than younger patients 
(P < 0.001), whereas patients with a family history of EC 
had lower preoperative DA scores (P = 0.032).
Association between preoperative DA scores and the 
survival of ESCC patients
In total, 260 patients with ESCC were followed up for 
91 months; they had a median survival time of 35 months 
(1–91  months). Patients with higher preoperative DA 
scores had a shorter OS than those with lower DA scores 
(37.1% for patients with a DA score of 2 vs. 52.6% and 76.4% 
for those with DA scores of 1 and 0, respectively, P < 0.001; 
Fig. 1a); similarly, DFS was significantly shorter in patients 
with higher DA scores than in those with lower DA scores 
(32.6% for patients with a DA score of 2 vs. 44.8% and 67.3% 
for those with DA scores of 1 and 0, respectively, P < 0.001; 
Fig. 1b). To assess the confounding effect of ESCC on the 
clinical stage, we further stratified patients into differ-
ent groups based on TNM stage (stages I–IIA and stages 
IIB–IV). The results showed that the DA score in patients 
with stages I–IIA and IIB–IV tumors were independently 
associated with OS (stages I–IIA, P =  0.032; stages IIB–
IV, P < 0.001; Fig. 2a, b) and DFS (stages I–IIA, P = 0.017; 
stages IIB–IV, P = 0.004; Fig. 2c, d).
Univariate analysis using the Cox proportional haz-
ard model showed that age, TNM stage, T category, N 
category, GPS, and DA scores were significantly asso-
ciated with OS; age, TNM stage, N category, and DA 
scores were significantly associated with DFS (Table  2). 
Although preoperative GPS was significantly predic-
tive of OS (P = 0.033), high CRP levels (>10 mg/L) and 
hypoalbuminemia (<35  g/L) were observed in only 39 
(15.0%) and 2 (0.8%) of 260 ESCC patients, respectively. 
Besides, only one patient was assigned a score of 2.
Furthermore, multivariate Cox regression analy-
sis indicated that DA score, age, and clinical stage were 
significantly associated with OS (P =  0.002, P =  0.001, 
P < 0.001, respectively) and DFS (P = 0.002, P = 0.030, 
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P < 0.001, respectively) in ESCC patients (Table 3). Com-
pared with the patients with a DA score of 0, hazard 
ratios [HRs, 95% confidence intervals (CIs)] for predict-
ing OS of patients with DA scores of 1 and 2 were 2.25 
(1.21–4.17, P  =  0.010) and 3.14 (1.66–5.92, P  <  0.001), 
respectively, and HRs (95% CIs) for predicting DFS of 
patients with DA scores of 1 and 2 were 1.86 (1.09–3.17, 
P = 0.023) and 2.68 (1.54–4.66, P < 0.001), respectively, 
compared with those with a DA score of 0.
Discussion
In the present study, we developed a novel prognos-
tic scoring system, DA score, based on plasma D-dimer 
and albumin and assessed its prognostic values in ESCC 
patients treated with transthoracic esophagectomy. The 
presented data demonstrate that the preoperative DA 
score was significantly associated with postoperative sur-
vival and could act as an independent prognostic marker 
for ESCC patients. Furthermore, after stratification by 
TNM stage, the preoperative DA score remained of great 
prognostic value in patients with early-stage (stages I–
IIA) and advanced-stage (stages IIB–IV) diseases. There-
fore, according to the preoperative DA score, which was 
independent of TNM stage, we can preemptively iden-
tify patients who are at increased risk of recurrence and 
who would have poor prognosis postoperatively; thus, 
Table 1 Preoperative DA score and clinicopathologic variables in 260 patients with ESCC
All values are presented as numbers of patients followed by percentages in parentheses
DA score D-dimer and albumin score, ESCC esophageal squamous cell carcinoma
a Patients whose first-grade relatives have a history of esophageal cancer
Characteristic No. of patients Score 0 (n = 55) Score 1 (n = 116) Score 2 (n = 89) P value
Sex 0.414
 Female 43 6 (14.0) 22 (51.2) 15 (34.9)
 Male 217 49 (22.6) 94 (43.3) 74 (34.1)
Age (years) <0.001
 ≤59 138 43 (31.2) 61 (44.2) 34 (24.6)
 >59 122 12 (9.8) 55 (45.1) 55 (45.1)
Tumor location 0.387
 Upper‑thoracic esophagus 21 4 (19.0) 10 (47.6) 7 (33.3)
 Middle‑thoracic esophagus 165 36 (21.8) 79 (47.9) 50 (30.3)
 Lower‑thoracic esophagus 74 15 (20.3) 27 (36.5) 33 (43.2)
Tumor size (cm) 0.079
 <4 126 27 (21.4) 64 (50.8) 35 (27.8)
 ≥4 134 28 (20.9) 52 (38.8) 54 (40.3)
Pathologic grade 0.383
 I/II 179 36 (20.1) 85 (47.5) 58 (32.4)
 III 81 19 (23.5) 31 (38.3) 31 (38.3)
TNM stage 0.390
 I–IIA 102 22 (21.6) 50 (49.0) 30 (29.4)
 IIB–IV 158 33 (20.9) 66 (41.8) 59 (37.3)
T category 0.373
 1 + 2 50 13 (26.0) 18 (36.0) 19 (38.0)
 3 + 4 210 42 (20.0) 98 (46.7) 70 (33.3)
N category 0.695
 0 107 22 (20.6) 51 (47.7) 34 (31.8)
 1 153 33 (21.6) 65 (42.5) 55 (35.9)
HBsAg 0.052
 Negative 238 46 (19.3) 109 (45.8) 83 (34.9)
 Positive 19 8 (42.1) 5 (26.3) 6 (31.6)
Family historya 0.032
 No 236 45 (19.1) 109 (46.2) 82 (34.7)
 Yes 24 10 (41.7) 7 (29.2) 7 (29.2)
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additional treatment, such as neoadjuvant chemotherapy 
and close follow-up, could be recommended.
GPS, an inflammation-based prognostic score, is widely 
recognized as a prognostic indicator for a variety of can-
cers, including liver, lung, breast, colorectal, and gastric 
cancers [24–27]. However, the clinical utility of GPS in EC 
patients remains controversial. Furthermore, some stud-
ies reported that inflammation and CRP levels are not 
commonly increased in ESCC patients [12]. Therefore, we 
evaluated the use of plasma D-dimer levels as a replace-
ment. D-dimer, a degradation product of fibrin, is an indi-
cator of hypercoagulability and endogenous fibrinolysis. 
Recently, studies revealed that D-dimer associated with 
cellular signaling systems and could promote cell growth 
and induce angiogenesis [28]. Buller et  al. [29] reported 
that D-dimer could also induce the spread of tumors by 
stimulating tumor cells to adhere to endothelial cells. 
Moreover, Diao et  al. [18] recently demonstrated that 
elevated plasma D-dimer level was associated with the 
progression of tumor and poor prognosis in EC, which 
was consistent with previous studies of colorectal, gas-
tric, breast, and lung cancers [16, 23]. In addition, it is 
well accepted that malnutrition is a predictor of survival 
in cancer, and serum albumin is considered a nutritional 
indicator [20, 21]. Previous studies showed that hypoalbu-
minemia was associated with poor survival in numerous 
solid cancers, including gastrointestinal, lung, and breast 
cancers [19, 30]. Therefore, cumulative scores based on 
preoperative D-dimer and albumin levels may be a poten-
tially predictive marker for prognosis of ESCC patients.
In recent years, some studies demonstrated that 
GPS was significantly associated with OS and DFS and 
could act as an independent prognostic marker for EC 
patients [31, 32]. In our study, preoperative GPS was 
also significantly predictive of OS in patients with ESCC 
(P = 0.037); however, the present data showed that only 
1 patient had a GPS of 2, resulting in decreased ben-
efit for predicting prognosis. As mentioned above, the 
severity of systemic inflammation and malnutrition in 
resectable EC might be insufficient to be effective as 
prognostic markers. Furthermore, multivariate analysis 
showed that GPS was not independently associated with 
OS or DFS. Matsuda et al. [12] reported similar results, 
of which only 2 of 199 EC patients were assigned a GPS 
score of 2, and GPS was shown to not be an independ-
ent prognostic factor for OS or DFS. The discordance in 
these studies might be explained by three factors. First, 
the difference of selected objects such as resectable and 
unresectable EC might lead to various results. Second, 
ethnicity and epidemiological differences may be the 
cause of the discrepancies between previous reports and 
our study. Third, whether the patients accepted neoad-
juvant treatment may explain the observed discordance. 
In this study, the D-dimer and albumin optimal cutoffs 
were defined as 0.5  μg/mL and 43.8  g/L, respectively, 
according to ROC analysis, and preoperative D-dimer 
and albumin levels were both significantly associated 
with OS and DFS in ESCC patients (data not shown). 
Thus, we devised a novel prognostic scoring system 
called DA score and found that the preoperative DA 
score was significantly associated with age and family 
history of EC, whereas there was no association between 
the DA score and TNM stage, T category, or N category, 
indicating that the preoperative DA score reflected the 
Fig. 1 Preoperative D‑dimer and albumin score (DA score) and postoperative survival of 260 patients with esophageal squamous cell carcinoma 
(ESCC). Patients with higher DA scores had significantly shorter OS (a, P < 0.001) and DFS (b, P < 0.001) than patients with lower DA scores
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patient’s individual status rather than tumor burden 
and progression. Kaplan–Meier analysis showed that 
patients with high preoperative DA scores had shorter 
OS and DFS compared with those with low preoperative 
DA scores. Multivariate analysis demonstrated that DA 
scores, along with age and TNM stage, were independ-
ent prognostic factors for postoperative survival. There-
fore, preoperative DA score was superior to GPS as a 
predictive factor in ESCC patients treated with transtho-
racic esophagectomy.
We acknowledge that our study has the following limi-
tations. First, our study was a retrospective study with a 
small sample size. Second, the present data were from a 
single institution. In addition, we did not include patients 
who underwent neoadjuvant treatment before surgery, 
which may have influenced our results.
Conclusions
In conclusion, our findings demonstrate that the preop-
erative DA score is associated with survival and can serve 
as an independent prognostic indicator in ESCC patients 
treated with transthoracic esophagectomy. We also con-
clude that DA score is superior to GPS as a predictive 
factor in patients with ESCC. Moreover, both plasma 
D-dimer and serum albumin are routinely measured in 
clinical practice, and the measurements are convenient, 
Fig. 2 Survival analyses of DA scores in patients with stages I–IIA and stages IIB–IV ESCC. OS curves of patients with a stages I–IIA and b stages IIB–
IV diseases and DFS curves of patients with c stages I–IIA and d stages IIB–IV diseases are shown according to distinct DA score
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Table 2 Univariate Cox regression analysis for survival of ESCC patients
HR hazard ratio, CI confidence interval; other abbreviations as in Table1
a Patients whose first-grade relatives have a history of esophageal cancer
Variable Overall survival Disease‑free survival
HR (95% CI) P value HR (95% CI) P value
Sex 0.846 0.576
 Females 1 1
 Males 0.96 (0.60–1.52) 1.14 (0.72–1.79)
Age (years) <0.001 <0.001
 ≤59 1 1
 >59 2.48 (1.73–3.57) 1.81 (1.30–2.52)
Tumor location 0.338 0.141
 Upper‑thoracic esophagus 1 1
 Middle‑thoracic esophagus 1.51 (0.73–3.13) 1.72 (0.87–3.41) 0.119
 Lower‑thoracic esophagus 1.20 (0.55–2.60) 1.30 (0.63–2.70) 0.479
Tumor size (cm) 0.291 0.276
 <4 1 1
 ≥4 1.21 (0.85–1.72) 1.20 (0.86–1.67)
Pathologic grade 0.423 0.534
 I/II 1 1
 III 1.17 (0.80–1.69) 1.12 (0.78–1.59)
TNM stage <0.001 <0.001
 I–IIA 1 1
 IIB–IV 3.16 (2.07–4.83) 3.24 (2.19–4.80)
T category 0.018 0.051
 1 + 2 1 1
 3 + 4 1.89 (1.12–3.21) 1.59 (0.99–2.52)
N category <0.001 <0.001
 0 1 1
 1 2.97 (1.97–4.47) 3.12 (2.13–4.57)
HBsAg 0.199 0.802
 Negative 1 1
 Positive 0.584 (0.26–1.33) 1.08 (0.58–2.00)
Family historya 0.486 0.271
 No 1 1
 Yes 0.79 (0.40–1.55) 0.70 (0.37–1.33)
Glasgow prognostic score 0.033 0.169
 0 1 1
 1 0.99 (0.60–1.62) 0.951 0.89 (0.56–1.43) 0.633
 2 14.70 (1.95–110.58) 0.008 6.26 (0.86–45.63) 0.070
DA score <0.001 <0.001
 0 1 1
 1 2.50 (1.37–4.59) 0.003 1.94 (1.15–3.27) 0.013
 2 4.12 (2.25–7.54) <0.001 2.99 (1.77–5.08) <0.001
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low-cost, and repeatable. Therefore, the DA score may 
be a simple and instructive indicator for the prognosis of 
ESCC patient in the future.
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